Biontech SE

Common Name
Biontech
Country
Germany
Sector
Healthcare
Industry
Biotechnology
Employees
6,772
Ticker
BNTX
Exchange
NASDAQ/NGS
Description
BioNTech SE is a biotechnology company, represented in the financial market through American Depositary Receipts (ADRs). This setup allows American investors to own shares in BioNTech, a German-based ...

Financial Statements of Biontech

Below are the financial statements of Biontech, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

All figures in billions of EUR202420232022
Revenues
2.75a
3.82a
17.31a
Cost of sales
-0.54a
-0.6a
-3a
Research and development expenses
-2.25a
-1.78a
-1.54a
Sales and marketing expenses
-0.07a
-0.06a
-0.06a
General and administrative expenses
-0.53a
-0.5a
-0.48a
Other operating expenses
-0.81a
-0.29a
-0.41a
Other operating income
0.14a
0.11a
0.82a
Operating profit / (loss)
-1.31a
0.69a
12.64a
Finance income
0.66a
0.52a
0.33a
Finance expenses
-0.03a
-0.02a
-0.02a
Profit / (loss) before tax
-0.68a
1.19a
12.95a
Income taxes
-0.01a
-0.26a
-3.52a
Net profit / (loss)
-0.67a
0.93a
9.43a

Verified Sources Behind Biontech’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Biontech’s data sources below and access millions more through our Disclosure Search.

a. Biontech's Annual Report 2024
Trace every data point back to Biontech’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?